List of Excipients in Branded Drug GLIADEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	GLIADEL	carmustine	24338-050	POLIFEPROSAN 20

GLIADEL Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 3, 2026

GLIADEL is a biodegradable intracranial implant containing 7.7 mg of carmustine in a polifeprosan 20 polymer wafer. Its commercial differentiation comes from local drug delivery, controlled polymer erosion, neurosurgical handling, and regulatory experience rather than from a conventional tablet excipient platform. The strongest opportunities are in follow-on implants, polymer engineering, manufacturing technology, combination products, and adjacent local-delivery systems.

What is GLIADEL and which excipients does it contain?

GLIADEL is a drug-device combination product for implantation into the resection cavity following surgery for malignant glioma. Each wafer contains 7.7 mg of carmustine and approximately 192 mg of the biodegradable polymer polifeprosan 20 [1].

Polifeprosan 20 is a copolymer derived from:

• 1,3-bis(p-carboxyphenoxy)propane
• Sebacic acid

The polymer is the principal excipient and delivery system. It is not a passive filler. Its composition, molecular weight, wafer geometry, porosity, hydration behavior, and erosion profile determine local carmustine release.

Product attribute	GLIADEL characteristic
Active ingredient	Carmustine, also known as BCNU
Strength	7.7 mg per wafer
Dosage form	Biodegradable intracranial implant
Polymer excipient	Polifeprosan 20
Route	Implantation into the surgical cavity
Maximum labeled placement	Up to eight wafers, subject to surgical judgment
Primary delivery objective	Local carmustine exposure with reduced reliance on systemic delivery
FDA regulatory category	Drug product with device-related delivery characteristics
Initial U.S. approval	1996
Current commercial sponsor historically associated with product	Eisai and predecessor companies

The FDA label identifies polymer degradation and carmustine release as central product characteristics. The wafer is designed to adhere to the resection cavity and degrade over time, allowing local release of carmustine [1].

How does the GLIADEL excipient system work?

The polymer matrix hydrates after implantation. Carmustine then diffuses from the matrix while polymer erosion contributes to product breakdown. The local delivery profile depends on the interaction of:

1. Polymer chemistry.
2. Carmustine loading.
3. Wafer thickness and diameter.
4. Polymer molecular weight and distribution.
5. Residual solvent and water content.
6. Manufacturing compression and drying conditions.
7. Sterilization exposure.
8. Packaging and storage conditions.

The formulation is therefore a critical quality attribute system, not merely a mixture of drug and excipient.

A follow-on manufacturer that changes the polymer ratio, wafer density, surface area, or degradation rate may alter:

• Initial burst release.
• Duration of local exposure.
• Local tissue tolerability.
• Cerebrospinal-fluid exposure.
• Wound healing.
• Risk of cerebral edema, seizures, infection, or impaired healing.
• Handling properties during neurosurgery.

These changes can create a regulatory bridge problem. A product with a different polymer or release profile may not qualify as a simple generic equivalent even if it contains the same amount of carmustine.

What formulation characteristics are commercially protectable?

The most valuable formulation claims are likely to concern the polymer-drug combination and product performance rather than the existence of carmustine alone.

Polymer composition

Potential claim categories include:

• Specific molar ratios of the two polymer monomers.
• Molecular-weight ranges.
• End-group chemistry.
• Degree of polymerization.
• Crystallinity or amorphous content.
• Polymer purity and residual monomer limits.
• Polymer-drug interaction parameters.

A narrow composition claim can protect release behavior that is difficult to reproduce without using the same polymer architecture.

Wafer geometry and physical structure

Commercially relevant claims may cover:

• Wafer thickness.
• Diameter and mass.
• Porosity.
• Density.
• Surface-area-to-volume ratio.
• Edge geometry.
• Layered or multilayer structures.
• Perforated or scored wafers.
• Flexible wafers that conform to irregular resection cavities.

Physical structure is especially important in intracranial surgery because the product must be placed in a confined cavity without obstructing closure or creating excessive mass effect.

Drug loading and release profile

Patentable features may include:

• Carmustine concentration.
• Drug distribution within the matrix.
• Burst-release limits.
• Release over a defined time period.
• Local concentration thresholds.
• Release in cerebrospinal fluid or simulated cerebrospinal fluid.
• Stability of carmustine during processing and storage.

A company could pursue a differentiated wafer with lower initial burst, longer release, or improved retention at the tumor margin. Those claims would need support from validated analytical and pharmacokinetic data.

Barrier and handling technology

Potential commercial improvements include:

• Anti-fragmentation coatings.
• Bioadhesive surfaces.
• Drug-free outer layers.
• Barrier films that reduce direct contact with healthy tissue.
• Improved flexibility.
• Color or imaging markers to assist surgical placement.
• Packaging that minimizes moisture uptake.
• Sterile handling systems that reduce wafer breakage.

These features may support separate device or combination-product claims even when the underlying polymer composition is no longer exclusive.

What patents protect GLIADEL?

GLIADEL originated from patent work on biodegradable polymer matrices for local delivery of chemotherapeutic agents. Legacy patent families covered polymer composition, drug incorporation, implant geometry, and localized treatment methods.

The principal commercial patent opportunity is no longer likely to be a broad foundational claim to a biodegradable carmustine wafer. The original U.S. patent estate has aged substantially, and the product was approved in 1996. Any surviving rights would require a current, jurisdiction-specific patent and terminal-disclaimer review.

Protection category	Commercial assessment
Broad biodegradable polymer matrix	Likely legacy or expired in the United States
Carmustine-loaded wafer composition	Likely exposed to follow-on development unless a later patent remains active
Manufacturing process	Potentially protectable through later-filed process patents
Wafer geometry	Potentially protectable if tied to functional performance
Release-control architecture	Stronger opportunity for new patent filings
Surgical placement method	Possible method-of-use protection, subject to claim scope
Packaging and sterilization	Narrower but commercially useful process protection
New active combinations	Potentially patentable, but requires clinical and regulatory support

A freedom-to-operate assessment should distinguish patent expiration from regulatory exclusivity. A patent can expire while manufacturing know-how, supplier qualification, analytical methods, and clinical experience continue to create practical barriers.

When did GLIADEL lose regulatory exclusivity?

GLIADEL received U.S. approval in 1996. Its orphan-drug exclusivity period would have run for seven years from approval, subject to the specific indication and regulatory history. That period was therefore exhausted long before the current market.

The product is not a biologic and has no biosimilar pathway. A competitor would pursue a generic, 505(b)(2), or other drug-device combination strategy rather than a biosimilar application.

Exclusivity type	GLIADEL status
Orphan-drug exclusivity	Historical seven-year period, expired
New chemical entity exclusivity	Not the current commercial barrier
Pediatric exclusivity	No material current exclusivity identified
Biosimilar exclusivity	Not applicable
Patent exclusivity	Requires current family-by-family review; foundational rights are historical
Regulatory exclusivity today	No known remaining original approval exclusivity that would independently block follow-on development

FDA approval does not establish that a follow-on manufacturer can rely on an abbreviated pathway. The complexity lies in demonstrating equivalence for a locally implanted polymer matrix.

What is the Orange Book status of GLIADEL?

GLIADEL was approved under NDA 020637 and has been listed in FDA drug databases as a carmustine implant product [2]. Orange Book analysis should examine:

• Whether the NDA remains active.
• Whether the product has current patent listings.
• Whether any listed patents have expired.
• Whether a therapeutic-equivalence code is available.
• Whether FDA has published a product-specific guidance document.
• Whether the reference product’s implant and polymer characteristics can be matched through an ANDA.

The Orange Book is not a complete measure of GLIADEL’s competitive protection. It may not capture manufacturing know-how, device-related controls, polymer supplier qualification, or unlisted process rights.

A company considering an ANDA must assess whether the product can meet the statutory requirements for sameness of active ingredient, dosage form, route, strength, and inactive ingredients. A different polymer architecture may force a 505(b)(2) strategy or a full NDA pathway.

Is a Paragraph IV challenge to GLIADEL commercially realistic?

A Paragraph IV strategy is possible only if a relevant patent is currently listed and not expired. A potential challenger would need to identify an active Orange Book-listed patent and certify that the patent is invalid, unenforceable, or not infringed.

The more difficult issue is product equivalence. A GLIADEL follow-on product may face several problems:

• The polymer may not qualify as the same inactive ingredient.
• Release kinetics may differ materially.
• FDA may require additional local-tolerance or clinical data.
• The implant may be treated as a complex dosage form.
• The applicant may need to establish equivalence using comparative performance testing rather than conventional pharmacokinetics.
• The product may require combination-product coordination between drug and device review functions.

A 505(b)(2) pathway may be more commercially practical where the applicant uses the same active ingredient but changes polymer composition, wafer dimensions, release characteristics, or manufacturing process.

What generic entry risks exist for GLIADEL?

Generic entry risk is moderate from a patent perspective but substantial from a technical and regulatory perspective.

Low-cost entry scenario

A company that reproduces the same carmustine loading, polifeprosan 20 chemistry, wafer geometry, manufacturing controls, and release profile could potentially reduce legal and regulatory uncertainty. The cost would shift toward:

• Specialized polymer manufacturing.
• Sterile processing.
• Stability studies.
• Combination-product quality systems.
• Neurosurgical handling validation.
• Commercial-scale wafer production.

Differentiated 505(b)(2) scenario

A company could avoid direct duplication by developing:

• A lower-burst formulation.
• A longer-lasting implant.
• A flexible or conformable wafer.
• A different biodegradable polymer.
• A dual-drug implant.
• A wafer for a different tumor type.
• A formulation compatible with immunotherapy or targeted therapy.

This approach could create new patent protection but would require stronger clinical evidence and more extensive regulatory work.

Substitution risk from nonimplant therapies

GLIADEL competes indirectly with systemic and device-based therapies, including:

• Temozolomide.
• Lomustine.
• Bevacizumab in selected settings.
• Tumor Treating Fields.
• Radiation-based treatment.
• Clinical-trial combinations.
• Local delivery systems using other polymers or nanoparticles.

The main commercial limitation is procedure dependence. GLIADEL is available only when tumor resection creates a suitable cavity. It cannot address patients who are not surgical candidates.

How strong is the GLIADEL patent estate?

The foundational estate is commercially weakened by age. The stronger current barriers are operational.

Estate component	Relative strength
Original polymer concept	Low, because of age and likely expiration
Brand-specific formulation	Moderate if supported by active later patents
Manufacturing process	Moderate to strong if proprietary and difficult to reproduce
Sterile wafer production	Moderate
Clinical and regulatory data package	Moderate
Surgeon familiarity and hospital protocols	Moderate commercial barrier
New combination claims	Potentially strong for a new entrant
International rights	Highly jurisdiction-dependent

Manufacturing know-how may be more defensible than broad composition claims. Important know-how could include polymer purification, solvent removal, compression conditions, wafer drying, sterilization validation, and stability-indicating assays for carmustine degradation products.

What excipient strategies offer the best commercial opportunities?

1. A bioequivalent polifeprosan 20 wafer

This is the closest follow-on opportunity. The commercial advantage would be a lower-cost equivalent product using the same or materially equivalent polymer system.

Key development requirements include:

• Polymer identity and characterization.
• Comparable drug loading.
• Comparative dissolution and degradation.
• Local-tissue compatibility.
• Sterility assurance.
• Physical integrity during surgery.
• Stability under refrigerated or controlled storage.

2. A next-generation biodegradable polymer

A new polymer could improve release control or reduce local toxicity. Candidates may include biodegradable polyesters, anhydride systems, polypeptide-based matrices, or hybrid polymer networks.

The opportunity is larger, but so is the evidence burden. A new excipient may require toxicology, local tolerance, degradation-product characterization, and clinical bridging.

3. A conformable implant

A thin film, mesh, sheet, or flexible wafer could improve contact with irregular resection cavities. This format could reduce product fragmentation and improve distribution around the surgical margin.

The principal patent opportunity would involve geometry, flexibility, adhesion, and controlled drug release.

4. A combination implant

A carmustine implant could be paired with another therapeutic agent, such as an antiangiogenic, radiosensitizer, immune-modulating agent, or targeted compound. Combination products create stronger intellectual-property potential but introduce compatibility and release-control challenges.

Each active ingredient may have a different stability profile. Carmustine is chemically reactive, so co-loading can generate degradation, phase separation, or altered polymer erosion.

5. Manufacturing and quality-control licensing

Licensing opportunities may exist in:

• Polymer synthesis.
• Drug-polymer mixing.
• Solvent casting.
• Compression molding.
• Sterile manufacturing.
• Moisture-control packaging.
• Release testing.
• Implant integrity inspection.

These assets can be licensed to a generic or specialty-pharma company even without owning a complete substitute product.

Which companies are challenging GLIADEL?

No major, widely established FDA-approved generic GLIADEL competitor is identified in the core public FDA product record. Competition has instead come from alternative glioma treatments, local-delivery technologies, and companies developing oncology drug-device platforms.

Potential counterparties for licensing or co-development include:

• Specialty oncology companies.
• Neurosurgical device manufacturers.
• Contract development and manufacturing organizations with implant capability.
• Polymer technology companies.
• Academic groups holding local-delivery patents.
• Developers of intratumoral or intracavitary oncology products.

The opportunity is more likely to arise through platform licensing or regional commercialization than through a conventional small-molecule generic launch.

What litigation and settlement issues affect GLIADEL?

The principal legal issues for a follow-on product would be:

1. Patent certification and Paragraph IV exposure.
2. Patent-term calculation and terminal disclaimers.
3. Infringement claims covering polymer composition or manufacturing.
4. Trade-secret disputes involving polymer processing.
5. Regulatory exclusivity and reliance on the reference product.
6. Combination-product classification.
7. Product-liability exposure involving neurological complications.

No current, broadly reported settlement framework defines the GLIADEL market. Any applicant would need to review active Orange Book listings, U.S. Patent and Trademark Office records, FDA correspondence, and litigation databases before launch planning.

What revenue exposure does GLIADEL create?

GLIADEL revenue is not separately disclosed in a consistently accessible public reporting line. The commercial opportunity should therefore be modeled from procedure volume and wafer utilization rather than from a confirmed product-level revenue figure.

A basic market model is:

Variable	Commercial driver
Annual malignant glioma resections	Addressable procedure pool
Percentage of eligible surgeries using an implant	Adoption rate
Average wafers per procedure	Product volume
Net price per wafer	Revenue per procedure
Hospital reimbursement	Purchaser economics
Neurosurgeon preference	Adoption durability
Reoperation rate	Recurrent-disease opportunity
Complication rate	Downside risk

The product can generate high revenue per surgical case because up to eight wafers may be used, but utilization is constrained by neurosurgical eligibility, reimbursement, hospital policy, and safety considerations.

How does GLIADEL compare with other local-delivery oncology products?

Attribute	GLIADEL	Systemic chemotherapy	Injectable local depot	Implantable device platform
Delivery site	Brain resection cavity	Systemic circulation	Local or regional site	Depends on device
Main excipient role	Biodegradable polymer matrix	Often conventional excipients	Depot-forming carrier	Device or reservoir
Regulatory complexity	High	Moderate	High	High
Surgical dependence	Yes	No	Often limited	Often yes
Patent opportunity	Polymer, geometry, release	Active ingredient and formulation	Carrier and release	Device plus method
Biosimilar pathway	No	No for small molecules	No	No
Generic pathway	Complex	Usually clearer	Complex	Highly product-specific

GLIADEL has a stronger local-delivery identity than a traditional pharmaceutical formulation. Its competitive advantage depends on placement at the tumor site, not systemic exposure.

What geographic coverage matters for GLIADEL follow-on products?

Patent and regulatory opportunities must be analyzed separately in each market:

• United States: FDA NDA, Orange Book, Paragraph IV, 505(b)(2), and combination-product requirements.
• European Union: centralized or national marketing authorization, medical-device interaction, and supplementary protection certificate analysis where relevant.
• Japan: PMDA review, local clinical requirements, and drug-device classification.
• China: National Medical Products Administration review, local manufacturing strategy, and hospital access.
• India: price sensitivity, local manufacturing, and patent-expiration exposure.
• Canada and Australia: local approval and reimbursement requirements.

A U.S. patent expiry does not create automatic freedom to commercialize in Europe or Asia. Polymer, process, and device patents may have different expiration dates and claim scope across jurisdictions.

Key Takeaways

• GLIADEL uses polifeprosan 20 as its principal excipient and drug-delivery matrix.
• The commercial value lies in controlled local delivery of carmustine after tumor resection.
• Original regulatory exclusivity is historical, and the foundational patent concept is aged.
• A follow-on product may face more regulatory and manufacturing complexity than patent risk.
• A true equivalent wafer offers the clearest generic opportunity.
• A new polymer, conformable implant, lower-burst formulation, or combination product offers stronger patent potential.
• GLIADEL is not eligible for a biosimilar strategy.
• A 505(b)(2) pathway may be more practical than an ANDA for materially different polymer or wafer designs.
• Manufacturing know-how, polymer qualification, sterility, packaging, and release testing may be the strongest practical barriers.
• Product-level revenue is not separately transparent in public reporting, so opportunity sizing should use procedure volume, wafer utilization, pricing, and reimbursement.

FAQs

Can polifeprosan 20 be replaced with another biodegradable polymer?

Yes, technically, but the replacement would change the product’s release, degradation, toxicity, and regulatory profile. A different polymer would likely require a 505(b)(2) or NDA strategy rather than a straightforward generic approach.

Is GLIADEL an implant, a drug, or a medical device?

It is a drug product delivered through a biodegradable implant matrix. FDA review treats the product as a drug with significant device-related manufacturing and performance characteristics.

Can a company sell carmustine in a conventional intracranial gel instead of a wafer?

Potentially, but the gel would be a different dosage form with different residence time, release kinetics, handling, and local-tolerance requirements. It would not automatically be substitutable for GLIADEL.

Are GLIADEL excipients subject to separate patent protection?

The polymer composition, drug-polymer matrix, wafer geometry, release profile, and manufacturing process may each be claimed separately. The enforceability and remaining term depend on the specific patent family and jurisdiction.

What is the most defensible new patent strategy around GLIADEL?

The strongest strategy is usually a product-performance claim tied to a new polymer architecture, controlled release profile, conformable geometry, improved tissue compatibility, or combination therapy. Broad claims to a biodegradable carmustine wafer are less likely to provide durable protection than narrowly defined, data-supported claims.

References

1. U.S. Food and Drug Administration. (2016). Gliadel 7.7 mg implant: Prescribing information. Eisai Inc.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, GLIADEL NDA 020637. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2022). Application submission under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Guidance for Industry.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2019). Drug-device combinations: General principles. Center for Devices and Radiological Health.